产品
编 号：F214557
分子式：C20H13F2N3
分子量：333.33
分子式：C20H13F2N3
分子量：333.33
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 1784751-19-4
产品详情
生物活性：
TA-02, an analog of SB 203580 (HY-10256), is a p38 MAPK inhibitor with an IC50 of 20 nM. TA-02 especially inhibits TGFBR-2. TA-02 exhibits similar cardiogenic properties as SB 203580 and SB 202190 (HY-10295).
体外研究：
TA-02 (5 μM) inhibits the phosphorylation of proteins downstream of p38α MAPK such asMAPKAPK2 and HSP27 during cardiogenesis. TA-02 at 5 μM concentration induces cardiogenesis, but also increases ATF-2 phosphorylation and MEF2C ?expression in contrast to what would be expected with a mechanism dependent on p38α MAPK inhibition.TA-02 induces T/Brachyury whereas SB203580 addition increased MESP1 and T/Brachyury transcripts.TA-02 significantly induces high NKX2-5 expression when applied between days 0-8.TA-02 is found to inhibit multiple targets with similar potency to p38α MAPK, such as p38α, p38β, JNK3, JNK2, CIT, CK1ε, DMPK2, JNK1, DDR1 CK1δ, MEK5, and ERBB2.TA-02 and SB203580 reduce the nuclear TCF/LEF-1 driven transcription of luciferase similar to DKK-1.TA-02 (5 nM-5 μM) inhibits p38 and increases the anti-inflammation effects of BDNF on inflammation in vitro.
TA-02, an analog of SB 203580 (HY-10256), is a p38 MAPK inhibitor with an IC50 of 20 nM. TA-02 especially inhibits TGFBR-2. TA-02 exhibits similar cardiogenic properties as SB 203580 and SB 202190 (HY-10295).
体外研究：
TA-02 (5 μM) inhibits the phosphorylation of proteins downstream of p38α MAPK such asMAPKAPK2 and HSP27 during cardiogenesis. TA-02 at 5 μM concentration induces cardiogenesis, but also increases ATF-2 phosphorylation and MEF2C ?expression in contrast to what would be expected with a mechanism dependent on p38α MAPK inhibition.TA-02 induces T/Brachyury whereas SB203580 addition increased MESP1 and T/Brachyury transcripts.TA-02 significantly induces high NKX2-5 expression when applied between days 0-8.TA-02 is found to inhibit multiple targets with similar potency to p38α MAPK, such as p38α, p38β, JNK3, JNK2, CIT, CK1ε, DMPK2, JNK1, DDR1 CK1δ, MEK5, and ERBB2.TA-02 and SB203580 reduce the nuclear TCF/LEF-1 driven transcription of luciferase similar to DKK-1.TA-02 (5 nM-5 μM) inhibits p38 and increases the anti-inflammation effects of BDNF on inflammation in vitro.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备